Jubilant Ingrevia Ltd

Jubilant Ingrev. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jubilant Ingrevia Ltd

₹ 544 -2.87%
26 Apr - close price
jubilantingrevia.com BSE: 543271 NSE : JUBLINGREA
About

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]

Key Points

Leadership[1]
# 40+ years of legacy in Chemicals space, started in 1978
# Global player in Pyridine + Beta, Vitamin B3 and Acetic Anhydride.
# Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies.
# Leading Low-Cost provider

Website BSE NSE
  • Market Cap ₹ 8,666 Cr.
  • Current Price ₹ 544
  • High / Low ₹ 582 / 379
  • Stock P/E 42.1
  • Book Value ₹ 170
  • Dividend Yield 0.92 %
  • ROCE 16.0 %
  • ROE 12.1 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 17.6%
  • Debtor days have improved from 111 to 39.1 days.
  • Company's working capital requirements have reduced from 130 days to 61.5 days

Cons

  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Chemicals Industry: Chemicals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
0 684 1,145 1,223 1,286 1,296 1,166 1,304 1,158 1,145 1,075 1,020 966
0 567 863 1,027 1,074 1,153 1,025 1,151 1,007 1,043 958 902 871
Operating Profit 0 117 282 195 213 142 141 153 151 102 117 118 96
OPM % 17% 25% 16% 17% 11% 12% 12% 13% 9% 11% 12% 10%
0 -10 6 7 9 9 10 7 7 9 8 9 9
Interest 0 7 13 7 5 6 4 5 7 6 11 13 15
Depreciation 0 22 32 31 30 31 31 31 30 30 32 34 34
Profit before tax 0 77 243 165 187 115 116 124 122 76 81 80 55
Tax % 30% 31% 33% 31% 40% 31% 32% 25% 31% 29% 28% 30%
0 54 168 111 129 69 79 84 92 52 58 57 39
EPS in Rs 0.00 3.41 10.56 6.96 8.10 4.31 4.98 5.29 5.75 3.28 3.62 3.61 2.42
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
0 684 4,949 4,773 4,206
0 567 4,108 4,224 3,774
Operating Profit -0 117 841 549 432
OPM % 17% 17% 11% 10%
0 -10 22 32 35
Interest 0 7 31 22 45
Depreciation 0 22 123 122 130
Profit before tax -0 77 709 437 292
Tax % 0% 30% 33% 30%
-0 54 477 308 206
EPS in Rs -3.40 3.41 29.93 19.31 12.93
Dividend Payout % 0% 10% 17% 26%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -15%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 1120%
TTM: -36%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 18%
1 Year: 29%
Return on Equity
10 Years: %
5 Years: %
3 Years: 15%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 0 16 16 16 16
Reserves -0 1,907 2,417 2,650 2,684
0 556 238 407 765
0 888 1,111 1,176 1,005
Total Liabilities 0 3,366 3,782 4,249 4,470
0 1,805 1,798 1,846 2,134
CWIP 0 65 174 525 452
Investments 0 50 6 8 10
0 1,446 1,804 1,870 1,875
Total Assets 0 3,366 3,782 4,249 4,470

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023
0 112 453 462
0 33 -71 -469
0 -72 -418 42
Net Cash Flow 0 73 -36 35

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 251 43 39
Inventory Days 601 117 146
Days Payable 685 103 113
Cash Conversion Cycle 167 57 72
Working Capital Days 269 59 61
ROCE % 8% 29% 16%

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
50.92% 50.92% 51.03% 51.10% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47%
18.70% 11.11% 12.42% 11.21% 10.19% 9.24% 8.40% 7.73% 6.15% 6.30% 6.35% 6.58%
1.44% 0.81% 0.60% 0.67% 0.70% 2.36% 4.89% 5.97% 6.72% 9.18% 11.17% 13.60%
28.75% 36.97% 35.75% 36.82% 37.44% 36.72% 35.03% 34.62% 34.83% 32.22% 30.17% 27.53%
0.20% 0.20% 0.20% 0.20% 0.20% 0.20% 0.19% 0.19% 0.82% 0.82% 0.82% 0.81%
No. of Shareholders 95,2351,49,9391,81,8471,91,4771,93,8581,95,7041,86,8951,85,0621,86,2941,73,5331,62,2021,50,388

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls